Late-onset frontotemporal dementia associated with a novel PGRN mutation.

Alzheimer's Disease and Cognitive Disorders Unit, Neurology Service, Hospital Clínic and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Journal of Neural Transmission (Impact Factor: 2.87). 02/2007; 114(8):1051-4. DOI: 10.1007/s00702-007-0716-6
Source: PubMed

ABSTRACT We describe a new mutation in the PGRN gene (A303AfsX57) associated with late-onset frontotemporal dementia and with "cat's eye" shaped intranuclear and cytoplasmatic ubiquitin immunoreactive inclusions in the neuropathological exam. The A303AfsX57 mutation is consistent with a nucleotide deletion in exon 8 (c908delC). This deletion causes a frameshift at codon 303 that introduces a premature termination codon (A303AfsX57).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Frontotemporal dementia (FTD) is one of the commonest forms of early-onset dementia, accounting for up to 20% of all dementia patients. Recently, it has been shown that mutations in progranulin gene (PGRN) cause many familial cases of FTD. Members of a family affected by FTD spectrum disorders were ascertained in Poland and Canada. Clinical, radiological, molecular, genetic, and pathological studies were performed. A sequencing analysis of PGRN exons 1-13 was performed in the proband. Genotyping of the identified PGRN mutation and pathological analysis was carried out in the proband's brother. The onset of symptoms of FTD in the proband included bradykinesia, apathy, and somnolence followed by changes in personality, cognitive deficits, and psychotic features. The proband's clinical diagnosis was FTD and parkinsonism (FTDP). DNA sequence analysis of PGRN revealed a novel, heterozygous mutation in exon 11 (g.2988_2989delCA, P439_R440fsX6). The mutation introduced a premature stop codon at position 444. The proband's brother with the same mutation had a different course first presenting as progressive non-fluent aphasia, and later evolving symptoms of behavioral variant of FTD. He also developed parkinsonism late in the disease course evolving into corticobasal syndrome. Pathological analysis in the brother revealed Frontotemporal Lobar Degeneration-Ubiquitin (FTLD-U)/TDP-43 positive pathology. The novel PGRN mutation is a disease-causing mutation and is associated with substantial intra-familial clinical heterogeneity. Although presenting features were different, rapid and substantial deterioration in the disease course was observed in both family members.
    Journal of Alzheimer's disease: JAD 10/2010; 22(4):1123-33. DOI:10.3233/JAD-2010-101413 · 3.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lewy body syndromes (mainly Parkinson's disease and dementia with Lewy bodies) share many clinical features and usually have a slowly progressive course. Some patients may show rapid symptoms progression. To evaluate clinical and neuropathological features of patients with a rapidly progressive diffuse Lewy Body disease. Review clinical records and pathological findings of 6 cases with diffuse Lewy Body disease and rapid disease progression (less than 18 months before death). Mean age at disease onset was 72.5 years, and mean disease duration was 9 months. Onset consisted of delirium in 3 patients and rapidly progressive dementia in the other three. All cases presented visual hallucinations and delusions; cognitive symptoms were fluctuating in two, parkinsonism occurred in four, and myoclonus in three. Brain MRI did not show cortical or basal ganglia hyperintensities. Periodic sharp waves were absent on EEG. 14.3.3 protein in CSF was negative. Myocardial (123) I-metaiodo-benzyl-guanidine SPECT showed marked reduction in tracer uptake in the 2 patients tested. Neuropathological studies did not identify any particular feature that could differentiate rapidly progressive diffuse Lewy body disease from classical diffuse Lewy body disease. Diffuse Lewy body disease is a possible cause of rapidly progressive dementia and should be included in the differential diagnosis of confusional states of undetermined cause. In patients with rapidly progressive dementia, the presence of fluctuating cognition, parkinsonism, hallucinations, delusions, or severe dysautonomia, should raise the suspicion of diffuse Lewy body disease. Neuroimaging studies such as (123) I-metaiodo-benzyl-guanidine myocardial scintigraphy may support the clinical diagnosis of diffuse Lewy body disease. © 2011 Movement Disorder Society.
    Movement Disorders 06/2011; 26(7):1316-23. DOI:10.1002/mds.23506 · 5.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Little is known about the role of progranulin (PGRN) in cervical cancer, which is an autocrine growth factor. We used immunohistochemistry, western blot, and ELISA to determine the expression levels of PGRN in cervical cancer and cervical cancer cell lines. Immortalized normal cervical cell line H8 with lower PGRN expression was treated with recombinant human PGRN (rhPGRN) and forced expression of PGRN by transfection and cell proliferation were determined. PGRN knockdown by siRNA was also performed in HeLa cells with high PGRN expression and cell proliferation was also determined. Furthermore, H8 cell xenograft mouse model was employed to determine if PGRN treatment could increase tumorigenesis of H8 cell xenograft. Our results showed that PGRN expression was significantly increased in cervical cancer tissue and high expression of PGRN is closely correlated with the degree of malignancy in cervical cancer cell lines. Increased PGRN expression or rhPGRN treatment increased the proliferation of H8 cells. Consistently, PGRN knockdown in HeLa cells by siRNA transfection reduced proliferation of HeLa cells. In H8 cell xenograft model, both intraperitoneal and intratumoral rhPGRN treatments increased tumorigenic capacity of H8 cell line. Our results suggested that PGRN could be used as both a diagnostic biomarker and therapeutic target.
    Cell Biochemistry and Biophysics 11/2014; 71(1). DOI:10.1007/s12013-014-0183-2 · 2.38 Impact Factor